Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4190764 | 0.87 | GRM4 (0.32) | — | |
| SCHEMBL16064857 | 0.87 | GRM4 (0.32) | — | |
| SCHEMBL901346 | 0.87 | GRM4 (0.32) | — | |
| SCHEMBL4186248 | 0.87 | GRM4 (0.32) | — | |
| SCHEMBL21013695 | 0.87 | GRM4 (0.32) | — | |
| SCHEMBL16064984 | 0.87 | GRM4 (0.32) | — | |
| SCHEMBL9738407 | 0.80 | CTSC (0.31) | — | |
| SCHEMBL16064929 | 0.75 | CTSC (0.33) | — | |
| SCHEMBL21013699 | 0.75 | CTSC (0.33) | — | |
| SCHEMBL30000521 | 0.70 | CYP1A2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665733-A1 | AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 | Bristol-Myers Squibb Company (US) | 2025-12-24 | — | — | EP | disclosed |
| WO-2024173323-A1 | AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-22 | — | — | WO | disclosed |
| US-20240238414-A1 | ANTI-PARASITIC IMMUNOLOGICAL COMPOSITIONS | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2024-07-18 | — | — | US | disclosed |
| CN-117865988-A | Tetrafused ring compound, preparation method and application thereof | 厦门宝太生物科技股份有限公司 | 2024-04-12 | — | — | CN | disclosed |
| US-11911464-B2 | Anti-parasitic immunological compositions | PROMMUNE, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20210290761-A1 | ANTI-PARASITIC IMMUNOLOGICAL COMPOSITIONS | AL-MURRANI, SAMER | 2021-09-23 | — | — | US | disclosed |
| US-20200172587-A1 | HYDROCHLORIDE SALTS OF C5A RECEPTOR AGONIST PEPTIDES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-06-04 | — | — | US | disclosed |
| EP-2945952-B1 | HETEROCYCLE-SUBSTITUED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME (US) | 2019-08-28 | — | — | EP | disclosed |
| EP-2970230-B1 | SUBSTITUTED BICYCLIC 1-CARBOXYLIC-ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C | BOEHRINGER INGELHEIM INT (DE) | 2019-05-22 | — | — | EP | disclosed |
| US-20190002480-A1 | Silane-Containing Heterocyclic Compounds and Methods of Use Thereof for the Treatment of Viral Diseases | MERCK SHARP & DOHME CORP. (US) | 2019-01-03 | — | — | US | disclosed |
| WO-2014110687-A1 | THIAZOLYL-SUBSTITUED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2014-07-24 | — | — | WO | disclosed |
| WO-2014110705-A1 | HETEROCYCLE-SUBSTITUED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2014-07-24 | — | — | WO | disclosed |
| WO-2014110706-A1 | THIOPHENE-SUBSTITUTED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2014-07-24 | — | — | WO | disclosed |
| WO-2014110688-A1 | THIOPHENE- SUB STITUED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2014-07-24 | — | — | WO | disclosed |
| US-20140199264-A1 | TETRACYCLIC XANTHENE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME LLC | 2014-07-17 | — | — | US | disclosed |
| US-20140170111-A1 | FUSED TETRACYCLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | Merck Sharp & Dohmn Corp. (US) | 2014-06-19 | — | — | US | disclosed |
| EP-2621931-A1 | TETRACYCLIC INDOLE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | Merck Sharp & Dohme Corp. (US) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012041014-A1 | TETRACYCLIC INDOLE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | disclosed |
| US-20080214529-A1 | SATURATED FUSED [1,2-b]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. | 2008-09-04 | — | — | US | disclosed |
| WO-2008073987-A1 | SATURATED FUSED [1,2-B] PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172587-A1 | HYDROCHLORIDE SALTS OF C5A RECEPTOR AGONIST PEPTIDES | C5AR1, C5AR2, C3AR1 | SLC6A9 1454/4885GBA1 2673/4885 |
| US-20140199264-A1 | TETRACYCLIC XANTHENE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | XDH, F12, RXRA | SLC6A9 4318/4885GBA1 30/4885 |
| US-20080214529-A1 | SATURATED FUSED [1,2-b]PYRIDAZINONE COMPOUNDS | HAVCR2, ZC3HAV1, NR1H4 | SLC6A9 4821/4885GBA1 458/4885 |
| US-20190002480-A1 | Silane-Containing Heterocyclic Compounds and Methods of Use Thereof for the Treatment of Viral Diseases | HAVCR2, SULT2A1, HBB | SLC6A9 3830/4885GBA1 290/4885 |
| US-20240238414-A1 | ANTI-PARASITIC IMMUNOLOGICAL COMPOSITIONS | C3AR1, C5AR1, C5AR2 | SLC6A9 4784/4885GBA1 1067/4885 |
| US-20140170111-A1 | FUSED TETRACYCLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | HAVCR2, ZC3HAV1, ZC3HAV1L | SLC6A9 1953/4885GBA1 6/4885 |
| US-11911464-B2 | Anti-parasitic immunological compositions | C3AR1, C5AR1, C5AR2 | SLC6A9 4784/4885GBA1 1067/4885 |
| US-20210290761-A1 | ANTI-PARASITIC IMMUNOLOGICAL COMPOSITIONS | C3AR1, C5AR1, C5AR2 | SLC6A9 4784/4885GBA1 1067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.